The sector has described one negative impact of changes to the R&D tax incentive as an 'unintended consequence'. However, it is understood officials have made it clear the negative 'hit' for small pre-revenue companies is intended. …
Latest Video
New Stories
-
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
BLS and Trexapharm move to bring TREXAVIVE to Australian patients
July 22, 2026 - - BioPharma -
Radiopharm Theranostics reports positive results in tumour trials
July 22, 2026 - - Australian Biotech -
Proteomics International and Healius team up to take Promarker tests national
July 22, 2026 - - Australian Biotech